Filipa Lynce, MD, Dana-Farber Cancer Institute, Boston, MA, presents findings from the TALAVE trial (NCT03964532), which assessed induction talazoparib followed by talazoparib and avelumab in patients with advanced breast cancer. Patients were divided based on BRCA1/2 mutational status, and the combination therapy was well tolerated, where patients with BRCA1/2-mutant and HER2-negative responded better to treatment. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.